BCR-ABL1 Kinase Domain Mutation Analysis (NGS) in UAE | 2000 AED | 2026 DHA Guidelines

تحليل طفرة نطاق الكيناز BCR-ABL1 في الإمارات | 2000 درهم | معتمد من هيئة الصحة بدبي

يُجرى هذا التحليل الجيني المتطور بواسطة تقنية تسلسل الجيل التالي (NGS) لمراقبة مقاومة مثبطات التيروزين كيناز لدى مرضى ابيضاض الدم النقوي المزمن (CML)، بدقة تشخيصية تبلغ 99.9% وخدمة سحب منزلي على أعلى مستوى.

✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing (Cert: INT/EGQ/2509DA/3139).
✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed specialists.
✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Clinical Overview & Test Comparison

BCR-ABL1 kinase domain mutation analysis is a pivotal next-generation sequencing (NGS) test for identifying resistance mutations in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor therapy. This advanced genomic profiling helps oncologists select second- or third-line TKIs to overcome drug resistance, ensuring personalized treatment and improved outcomes.

Feature	Our Test (NGS)	Closest Alternative (Sanger Sequencing)
Methodology	Next-Generation Sequencing (NGS) with unique molecular identifiers	Sanger sequencing
Sensitivity	>99.9% for mutations down to 1% variant allele fraction	15–20% variant allele fraction
Turnaround Time	14–21 days	7–10 days
Price	2000 AED	Similar price range

Physician Insight & Safety Protocol

“Interpreting BCR-ABL1 mutation results requires a multidisciplinary approach; a mutation detected does not always demand an immediate therapy change. I strongly advise discussing the report with your treating hematologist-oncologist to correlate with clinical and molecular response milestones.” — Dr. PRABHAKAR REDDY, DHA License No. 61713011.

⚠️ Medication Warning

Do not discontinue prescribed medication without consulting your doctor. Abrupt cessation of TKI therapy can cause rapid disease progression.

🛑 Safety Exclusion Criteria & ER Red Flags

Exclusion for Bone Marrow Aspirate: Severe coagulopathy (INR >1.5, platelets <50,000/µL), active infection at aspiration site, or patient unable to lie prone. Peripheral blood collection is safe for most patients and preferred for mutation analysis when clinically adequate.
Emergency Red Flags After Sample Collection: Seek immediate medical attention if you experience sudden severe bone pain, fever with neutropenia (temperature >38.3°C and ANC <500 cells/µL), or neurological symptoms suggestive of blast crisis.
Pre-test Information: A valid DHA-licensed physician’s prescription is required. No specific drug washout is needed for this test; however, for optimal sensitivity, peripheral blood should be drawn immediately before the next scheduled TKI dose (if applicable). Bone marrow aspirate must be scheduled at our partner hospital under sterile conditions.

Patient FAQ & Clinical Guidance

What does a BCR-ABL1 kinase domain mutation test detect?

This test identifies specific genetic mutations within the BCR-ABL1 kinase domain that can cause resistance to tyrosine kinase inhibitors, guiding precise CML treatment adjustments.

يكشف هذا الاختبار عن طفرات جينية محددة داخل نطاق الكيناز لـ BCR-ABL1 مسؤولة عن مقاومة مثبطات التيروزين كيناز، مما يوجه تعديلات دقيقة في علاج ابيضاض الدم النقوي المزمن.

How is the sample collected, and is it painful?

The test requires either a peripheral blood draw (similar to a routine blood test) or a bone marrow aspirate; peripheral blood is usually painless, while marrow aspiration is performed under local anesthesia to minimize discomfort.

يُجرى الاختبار على عينة من الدم المحيطي (سحب دم عادي) أو نخاع العظم؛ سحب الدم غير مؤلم عادة، أما سحب النخاع فيتم تحت تأثير التخدير الموضعي للحد من الانزعاج.

How long does it take to get results, and what do I do after?

Results are typically available within 14–21 days; upon receiving the report, schedule a telephonic clinical guidance session with our DHA-licensed oncologist for a comprehensive interpretation and next steps.

تظهر النتائج عادةً خلال 14 إلى 21 يومًا؛ وبعد استلام التقرير، احجز جلسة توجيه سريري هاتفية مع أخصائي الأورام المرخص هيئة الصحة بدبي للحصول على تفسير شامل والخطوات التالية.

UAE Healthcare Compliance: This service strictly adheres to Federal Decree-Law No. 41 of 2024 (Art. 87) on Health Data, the CDS Law 2026 (Minors) requiring parental consent for patients under 18, and UAE PDPL (Federal Decree-Law No. 45 of 2021) for data privacy. All testing is performed under DHA facility license No. 9834453.

Primary Clinical Specialists for This:

Consultant Hematologist-Oncologist (CML & TKI management)
Consultant Molecular Pathologist (NGS interpretation)
Consultant Clinical Geneticist (hereditary susceptibility and family counseling)

دعم ثنائي اللغة متاح